The Contract Biomanufacturing Market Outlook to 2017

NEW YORK, March 7, 2013 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:

The Contract Biomanufacturing Market Outlook to 2017
http://www.reportlinker.com/p01118464/The-Contract-Biomanufacturing-Market-Outlook-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical

Introduction

The volume demand for biologics active pharmaceutical ingredients (API) from 2011-2017 is set to show a 20% annual increase. Combined with a boost in biosimilars, the biologics contract manufacturing market is forecast to grow 9% per year over the same period.

Scope

• Develop a winning expansion and outsourcing strategy to grow your market share with forecasts through to 2017
• Assess the areas to target and use your findings to help increase profits with information on drivers and resistors of outsourced biomanufacturing
• Use the forecast for biologic and CMO market to adapt your strategy and ensure you're commercially successful
• With analysis on the 5 leading players you will understand what your competitors are doing and what actions you can take to stay competitive
The biological contract manufacturing organization (CMO) market will grow at a compound annual growth rate (CAGR) of 9.4% between 2011 and 2017. Mammalian contract manufacturing accounted for almost two thirds of the market in 2012, which was estimated at a size of $3bn.

Increasing API demand driven by biologics market growth and an increase in the number of late-stage clinical trials and approved biotech products will be the biggest drivers of the bio-CMO market.

Reasons to Buy

• What is the state of contract biomanufacturing in emerging regions?
• Who are the leading bio-CMOs and what are their strategies, strengths and weaknesses?
• What is the most attractive area of investment in the biologics market?

Table of Contents

Overview 4
Catalyst 4
–– Summary 4
Executive Summary 5
Market Overview 6
Definition 6
Segmentation 6
–– Categories of CMOs and services offered 7
References 9
Market Dynamics 10
Drivers 10
–– Growth of large molecule market 10
–– Cost savings 11
–– Risk reduction and risk sharing 11
–– Lead-time saving 11
–– Access to expertise and technology 12
–– Orphan drugs 12
–– Growth in emerging markets 13
–– Biosimilars 13
Resistors 14
–– Increasing yields and disposable technology 14
–– Overcapacity and pharma's increasing in-house capacity 14
–– Regulatory uncertainty over biosimilars 14
Market forecasts 15
–– Microbial and mammalian drug market 15
–– Microbial vs mammalian CMO market 15
–– Biosimilars 15
–– Biomanufacturing installed base 16
Contract biomanufacturing in emerging regions 17
References 17
Leading Players 19
Summary 19
Introduction 19
Boehringer Ingelheim 20
–– Overview and capabilities 20
–– Partnerships, deals, and expansion plans 20
–– SWOT analysis 21
Lonza 21
–– Overview and capabilities 21
–– Partnerships, deals, and expansion plans 22
–– SWOT analysis 22
Sandoz 23
–– Overview and capabilities 23
–– Partnerships, deals, and expansion plans 23
–– SWOT analysis 23
Fujifilm Diosynth Biotechnologies 24
–– Overview and capabilities 24
–– Partnerships, deals, and expansion plans 24
–– SWOT analysis 24
DSM 25
–– Overview and capabilities 25
–– Partnerships, deals, and expansion plans 25
–– SWOT analysis 26
References 26
Appendix 29
Methodology 29
–– Pharmaceutical market 29
–– Bio-CMO market 29
References 29
Table 1: Categories of CMOs and services offered 7
Figure 1: Biopharma value chain 7
Figure 2: Small vs large molecule pharma market ($bn), 2008–17 10
Figure 3: Number of orphan drug NMEs historically and
forecasted average in the US, 2005–16 12
Figure 4: Biopharmaceutical drug market by major product
group ($bn), 2011–17 15
Figure 5: Mammalian and microbial API CMO market ($bn),
2010–17 16
Figure 6: Comparison of leading bio-CMOs by capability 19

Companies Mentioned

First Aviation Services Inc., Hutchison 3G UK Limited

To order this report:
Biopharmaceutical Industry:
The Contract Biomanufacturing Market Outlook to 2017

_________________________
Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.